Literature DB >> 21674576

Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis.

Animesh Pardanani1, Terra L Lasho, Christy M Finke, Ayalew Tefferi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21674576     DOI: 10.1002/ajh.22058

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  6 in total

Review 1.  [Myeloproliferative neoplasms: histopathological and molecular pathological diagnosis].

Authors:  K Hussein; G Büsche; J Schlue; U Lehmann; H Kreipe
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

2.  Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis.

Authors:  K Gowin; S Verstovsek; N Daver; N Pemmaraju; R Valdez; H Kosiorek; A Dueck; R Mesa
Journal:  Leuk Res       Date:  2015-04-17       Impact factor: 3.156

Review 3.  Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases.

Authors:  Xin He; Zhigang Chen; Yangyan Jiang; Xi Qiu; Xiaoying Zhao
Journal:  J Hematol Oncol       Date:  2013-01-25       Impact factor: 17.388

Review 4.  Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Blood Cancer J       Date:  2015-08-14       Impact factor: 11.037

5.  A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis.

Authors:  A Pardanani; A Tefferi; C Jamieson; N Y Gabrail; C Lebedinsky; G Gao; F Liu; C Xu; H Cao; M Talpaz
Journal:  Blood Cancer J       Date:  2015-08-07       Impact factor: 11.037

Review 6.  Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses.

Authors:  Vibe Skov
Journal:  Cancers (Basel)       Date:  2020-08-06       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.